| Overview |
| bs-7084R-Cy5 |
| NOD2 Polyclonal Antibody, Cy5 Conjugated |
| WB, FCM |
| Human |
| Mouse, Rat, Dog, Cow, Pig, Horse, Rabbit |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CARD15 |
| 251-350/1040 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 64127 |
| Q9HC29 |
| Cytoplasm |
| ACUG; Arthrocutaneouveal granulomatosis; BLAU; CARD15; Caspase recruitment domain protein 15; Caspase recruitment domain-containing protein 15; IBD1; Inflammatory bowel disease protein 1; LRR containing protein; LRR-containing protein; Nod2; NOD2 protein; NOD2_HUMAN; NOD2B; nucleotide binding oligomerization domain 2; nucleotide-binding oligomerization domain 2; Nucleotide-binding oligomerization domain-containing protein 2; PSORAS1. |
| Defects in NOD2 are the cause of sarcoidosis early-onset (EOS) . EOS is a form of sarcoidosis manifesting in children younger than 4 years of age. Sarcoidosis is an idiopathic, systemic, inflammatory disease characterized by the formation of immune granulomas in involved organs. Granulomas predominantly invade the lungs and the lymphatic system, but also skin, liver, spleen, eyes and other organs may be involved. Early-onset sarcoidosis is quite rare and has a distinct triad of skin, joint and eye disorders, without apparent pulmonary involvement. Compared with an asymptomatic and sometimes naturally disappearing course of the disease in older children, early-onset sarcoidosis is progressive and in many cases causes severe complications, such as blindness, joint destruction and visceral involvement. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
Powered by Bioz